CC2018: Reducing Surgical Wound Infections in Colon and Rectal Surgery (PtS)
This session has been identified and designated as Credit to Address Regulatory Mandate for Patient Safety.
The ability to reduce surgical wound infections after colorectal surgery has been demonstrated using a concerted “bundle” of initiatives. This session will outline the problem and why it matters. Then tips will be given regarding how to set up and implement a “bundle” for your hospital.
Najjia N. Mahmoud, MD, FACS, FASCRS, Philadelphia, PA
- Defining Surgical Site Infections (SSI): Why Should I Care?
Traci L. Hedrick, MD, FACS, FACRS, Charlottesville, VA
- SSI Bundles: Do I Need All This?
Emre Gorgun, MD, FACS, FASCRS, Cleveland, OH
- Results: Does This Make a Difference?
Elizabeth C. Wick, MD, FACS, San Francisco, CA
- Constructing a Program: How to Get Started at Your Institution
Christopher R. Mantyh, MD, FACS, FASCRS, Durham, NC
- Practicing surgeons
- Apply new knowledge and ideas to improve their surgical practice
- Adapt concepts and quality measures in support of research advancements
- Enhance the quality of patient care
(Download the full list of disclosures.)
Faculty and Disclosures
Najjia N. Mahmoud, MD, FACS, FASCRS, Philadelphia, PA - No Disclosures
Traci L. Hedrick, MD, FACS, FACRS, Charlottesville, VA - No Disclosures
Emre Gorgun, MD, FACS, FASCRS, Cleveland, OH - No Disclosures
Elizabeth C. Wick, MD, FACS, San Francisco, CA - No Disclosures
Christopher R. Mantyh, MD, FACS, FASCRS, Durham, NC - No Disclosures
Program Committee and Disclosures
CHAIR: Henri R. Ford, MD, MHA, FACS, FAAP, FRCSEng(Hon), Miami, FL - No Disclosures
VICE-CHAIR: David T. Cooke, MD, FACS, Sacramento, CA - No Disclosures
David C. Borgstrom, MD, FACS, Morgantown, WV - No Disclosures
Daniel L. Dent, MD, FACS, San Antonio, TX - No Disclosures
Roger R. Dmochowski, MD, FACS, Nashville, TN - Allergen: Honoraria: Consultant
Audra A. Duncan, MD, FACS, London, ON - No Disclosures
Mariam F. Eskander, MD, Boston, MA - No Disclosures
Paula Ferrada, MD, FACS, Richmond, VA - No Disclosures
Neil H. Hyman, MD, FACS, Chicago, IL - No Disclosures
Martin S. Karpeh, Jr., MD, FACS, New York, NY - No Disclosures
Dennis H. Kraus, MD, FACS, New York, NY - No Disclosures
Kenneth W. Sharp, MD, FACS, Nashville, TN - No Disclosures
David A. Spain, MD, FACS, Stanford, CA - No Disclosures
Mary T. Hawn, MD, FACS, Stanford, CA - No Disclosures
Daniel M. Herron, MD, FACS, FASBMS, New York, NY - No Disclosures
Barbara Lee Bass, MD, FACS, FRCS(Hon), Houston, TX - No Disclosures
Quan-Yang Duh, MD, FACS, San Francisco, CA - No Disclosures
B. J. Hancock, MD, FACS, FRCSC, Winnipeg, MB - No Disclosures
Ronald V. Maier, MD, FACS, FRCSEd(Hon), Seattle, WA - No Disclosures
Valerie W. Rusch, MD, FACS, New York, NY - No Disclosures
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. Members of the program committee and speakers were required to disclose all financial relationships. The ACCME defines a ‘commercial interest’ as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients”. It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers “relevant” financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the session. The planning committee members and speakers were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias during a session, please advise us of the circumstances on the session evaluation form.
Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.
The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.
Note: Residents will receive a Certificate of Completion.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Self Assessment Credit
- 1.50 Certificate of Completion